The U.S. Food and Drug Administration approved Cytokinetics’ new therapy Myqorzo for obstructive hypertrophic cardiomyopathy, marking the biotech’s first U.S. drug approval. Company disclosures indicate commercialization will begin in late January, with pricing still to be announced. Myqorzo will compete against an established Bristol Myers Squibb rival that has generated over $1 billion in annual sales, creating an immediate commercial contest in a rare cardiomyopathy segment. The approval moves Cytokinetics from pure R&D developer toward an operating commercial biotech and may reshape valuation and partnering dynamics.